Amedeo Smart

Free Medical Literature Service



HIV Infection

  Free Subscription

Articles published in
Antivir Ther
    October 2022
  1. ARA T, Endo T, Goto H, Kasahara K, et al
    Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor.
    Antivir Ther. 2022;27:13596535221126828.
    >> Share

    August 2022
  2. ALEJOS B, Diez C, Galindo MJ, Lopez JC, et al
    Progress in the quality of care for newly diagnosed people with HIV in Spain (2004-2019).
    Antivir Ther. 2022;27:13596535221112729.
    >> Share

  3. BELLO G, Kagoli M, Chipeta S, Auld A, et al
    Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi.
    Antivir Ther. 2022;27:13596535221121225.
    >> Share

  4. ALVAREZ E, Campbell L, Tinago W, Garcia-Leon A, et al
    The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
    Antivir Ther. 2022;27:13596535221094898.
    >> Share

  5. VAN DER VEER MA, Jacobs TG, Bukkems LH, Colbers AP, et al
    Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report.
    Antivir Ther. 2022;27:13596535221119932.
    >> Share

    June 2022
  6. MUSENGIMANA G, Tuyishime E, Kiromera A, Malamba SS, et al
    Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Antivir Ther. 2022;27:13596535221102690.
    >> Share

  7. WISCH JK, Cooley SA, Yarasheski KE, Cade WT, et al
    Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV.
    Antivir Ther. 2022;27:13596535221109748.
    >> Share

  8. EUROPEAN PREGNANCY AND PAEDIAT, Lyons A, Thompson L, Chappell E, et al
    Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
    Antivir Ther. 2022;27:13596535221092182.
    >> Share

    April 2022
  9. LEE WA, Cheng AK
    Tenofovir alafenamide fumarate.
    Antivir Ther. 2022;27:13596535211067600.
    >> Share

  10. ABDOOL KARIM SS, Baxter C, Abdool Karim Q
    Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Antivir Ther. 2022;27:13596535211067589.
    >> Share

  11. CHOUDHARY MC, Mellors JW
    The transformation of HIV therapy: One pill once a day.
    Antivir Ther. 2022;27:13596535211062396.
    >> Share

  12. ALTON G, Samuel C, Reddi A
    Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case.
    Antivir Ther. 2022;27:13596535211068617.
    >> Share

  13. SCHINAZI RF, Patel D, Ehteshami M
    The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.
    Antivir Ther. 2022;27:13596535211067599.
    >> Share

  14. YANG T, Oliyai R, Kent KM
    The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Antivir Ther. 2022;27:13596535211067606.
    >> Share

    November 2021
  15. MOLINA JM, Ene L, Cahn P, Fatkenheuer G, et al
    Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
    Antivir Ther. 2021;26.
    >> Share

  16. RIVERA AS, Machenry S, Okpokwu J, Olatunde B, et al
    HBV co-infection is associated with persistently elevated liver stiffness measurement in HIV-positive adults: A 6-year single-centre cohort study in Nigeria.
    Antivir Ther. 2021;26.
    >> Share

  17. PRESSIAT C, Dainguy E, Treluyer JM, Yonaba C, et al
    Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.
    Antivir Ther. 2021;26.
    >> Share

    May 2021
  18. MAGGIOLO F, Gianotti N, Comi L, Di Filippo E, et al
    Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
    Antivir Ther. 2021;26.
    >> Share

  19. SCHEIBE K, Urbanska A, Jakubowski P, Hlebowicz M, et al
    Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Antivir Ther. 2021;26.
    >> Share

  20. FARINACCI D, Ciccullo A, Lombardi F, Moschese D, et al
    Evaluation of doravirine-based regimen population target in a large Italian clinical center.
    Antivir Ther. 2021;26.
    >> Share

  21. CICCULLO A, Baldin G, Borghetti A, Di Giambenedetto S, et al
    Real-life findings on the impact of the COVID-19 pandemic on HIV care.
    Antivir Ther. 2021;26.
    >> Share

    April 2021
  22. LIPINSKI J, Margevicius S, Schluchter MD, Wilson DL, et al
    Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy.
    Antivir Ther. 2021 Apr 26. doi: 10.3851/IMP3389.
    >> Share

  23. JIAMSAKUL A, Azwa I, Zhang F, Yunihastuti E, et al
    Treatment modification after second-line failure among people living with HIV in the Asia-Pacific.
    Antivir Ther. 2021 Apr 12. doi: 10.3851/IMP3388.
    >> Share

    March 2021
  24. YIN MT, Bucovsky M, Williams J, Brunjes D, et al
    Effect of Vitamin D3 and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV.
    Antivir Ther. 2021 Mar 11. doi: 10.3851/IMP3386.
    >> Share

  25. DORWARD J, Gbinigie O, Cai T, Roberts NW, et al
    The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.
    Antivir Ther. 2021 Mar 11. doi: 10.3851/IMP3385.
    >> Share

    January 2021
  26. ALEJOS B, Suarez-Garcia I, Bernardino JI, Blanco JR, et al
    Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.
    Antivir Ther. 2021 Jan 20. doi: 10.3851/IMP3380.
    >> Share

  27. LEZCANO CARDUZ VP, Alba NA, Almagro EG, Pernaute OS, et al
    Cytomegalovirus infection associated with severe intraocular inflammation in an HIV patient: a case report.
    Antivir Ther. 2021 Jan 20. doi: 10.3851/IMP3381.
    >> Share

  28. BIJKER R, Kumarasamy N, Kiertiburanakul S, Pujari S, et al
    An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia.
    Antivir Ther. 2021 Jan 19. doi: 10.3851/IMP3379.
    >> Share

  29. POST FA, Hamzah L
    Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?
    Antivir Ther. 2021 Jan 18. doi: 10.3851/IMP3378.
    >> Share

  30. FLORIDIA M, Masuelli G, Tassis B, Franceschetti L, et al
    Weight gain during pregnancy in women with HIV receiving different antiretroviral regimens.
    Antivir Ther. 2021 Jan 15. doi: 10.3851/IMP3376.
    >> Share

  31. KOUAME GM, Gabillard D, Moh R, Badje A, et al
    Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4(+) cell counts.
    Antivir Ther. 2021;26.
    >> Share

  32. LEE JE, Lee SO, Heo J, Kim DW, et al
    Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
    Antivir Ther. 2021;26.
    >> Share

  33. UGARTE A, De la Mora L, Martinez-Rebollar M, Mallolas J, et al
    An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis.
    Antivir Ther. 2021;26.
    >> Share

    November 2020
  34. BRUNET L, Wyatt C, Hsu R, Mounzer K, et al
    Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.
    Antivir Ther. 2020 Nov 19. doi: 10.3851/IMP3373.
    >> Share

    September 2020
  35. PILLAY T, Cornell M, Fox MP, Euvrard J, et al
    Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study.
    Antivir Ther. 2020 Sep 22. doi: 10.3851/IMP3371.
    >> Share

    June 2020
  36. ZHANG Q, Li X, Qiao S, Shen Z, et al
    Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China.
    Antivir Ther. 2020 Jun 1. doi: 10.3851/IMP3360.
    >> Share

    April 2020
  37. BLACKMAN AL, Heil EL, Devanathan AS, Pandit NS, et al
    The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Antivir Ther. 2020 Apr 28. doi: 10.3851/IMP3355.
    >> Share

  38. HOFFMANN C, Schewe K, Fenske S, Buhk T, et al
    Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
    Antivir Ther. 2020 Apr 1. doi: 10.3851/IMP3351.
    >> Share

    March 2020
  39. ARENAS-PINTO A, Stohr W, Khoo S, Clarke A, et al
    Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.
    Antivir Ther. 2020 Mar 23. doi: 10.3851/IMP3340.
    >> Share

    February 2020
  40. BARANEK B, Wang S, Cheung AM, Mishra S, et al
    The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
    Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016